Pharmaceutical Management Agency

Future Procurement Opportunity (FPO) - Supply of insulin pumps, insulin pump consumables, and continuous glucose monitoring (CGM) devices

Pharmac is planning on issuing a competitive process for supply of insulin pumps, insulin pump consumables, and continuous glucose monitoring (CGM) devices used in the management of diabetes. Insulin pumps and insulin pump consumables are currently funded, CGM devices are not currently funded.

Information related to the funding of insulin pumps and insulin pump consumables, including eligibility criteria, is available on the Pharmac website. https://pharmac.govt.nz/medicine-funding-and-supply/medicine-notices/insulinpumps/

The approximate gross annual expenditure for insulin pumps and insulin pump consumables in the 2021/22 financial year (1 July 2021 to 30 June 2022) was $13 million. This was made up of approximately $7 million for insulin pumps and $6 million for insulin pump consumables. Some of these products are subject to confidential pricing arrangements which reduce their net cost and expenditure.

CGM devices are used to monitor blood glucose levels. CGM devices can be used independently of insulin pumps, and some CGMs can be integrated with insulin pumps. CGMs are not currently funded. You can view the status of the CGM funding applications we have received and assessed on the Pharmac Application tracker. https://connect.pharmac.govt.nz/apptracker/s/

Indicative RFx Release Date: Q3 2023
Project Status: Initial development
Indicative Total Value: $100M +